Glenmark and SaNOtize announce positive Results from Phase 3 Clinical Trial of NONS (FabiSpray®) in Non-Hospitalized Adult Indian Patients with COVID-19

Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94% in 24 hours and 99% in 48 hours. NONS was safe and well tolerated in COVID-19 patients. Glenmark received manufacturing and marketing approval from India’s drug regulator for Nitric Oxide Nasal Spray (NONS) as part of accelerated approval […]

thaipr.net

10 ก.พ. 65
1 2,193 2,194 2,195 2,196 2,197 3,052